Zhitong Finance App News, Shiyao Group (01093) announced that the phase III clinical trial of SYS6043 developed by the group for first-line treatment of recurrent or metastatic triple-negative breast cancer that cannot be surgically resected has been officially launched at the first research center in China.

This product is an antibody-conjugated drug (ADC) that targets B7-H3 developed by the Group. The antibody part can specifically bind to the cell surface expressing B7-H3 and internalize it into the cell; its linker-drug (Linker-Drug) is a tetrapeptide ligand-conjugated topoisomerase I inhibitor, which can release small molecules of toxins to kill tumor cells through protease-specific cleavage, and exerts a bystander effect on non-specific killing surrounding tumor tissue cells. Unlike antibodies that use traditional wild-type crystallizable fragments (Fc), this product can reduce lymphocyte uptake and reduce the risk of off-target toxicity, thereby improving the safety of treatment.

The clinical trial launched this time is a randomized, open, multi-center phase III clinical trial. The purpose is to evaluate the clinical efficacy and safety of this product among participants who chose chemotherapy to treat recurrent or metastatic triple-negative breast cancer that cannot be surgically resected on the first line. Currently, the recruitment and screening of participants for this phase III clinical trial is being actively promoted.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.